Teva Concludes Nationwide Opioids Settlement Agreement
Teva Pharmaceuticals, A U.S. Affiliate Of Teva Pharmaceutical Industries Ltd. (Nyse And Tase: Teva), Today Announced That The Company Has Fully Resolved Its Nationwide Settlement Agreement Related To Opioid Claims Brought By U.S. States, Their Subdivisions, And Special Districts, And Has Reached A Separate Settlement With The Final State Of Nevada. Teva Will Pay Nevada $193 Million Over 20 Years (Including All Fees And Costs), And This Settlement Resolves The Case Prior To Trial, Which Had Been Scheduled To Begin In August 2023.With These Developments, Teva Has Resolved Its Opioid Litigation With All 50 U.S. States And More Than 99% Of The Litigating Subdivisions And Special Districts. The Company Anticipates Making Its First Payment Under The Nationwide Opioids Settlement Agreement In The Second Half Of 2023. Teva Has Already Begun Shipments Of Its Generic Version Of The Life-Saving Medication, Narcan
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
